Payment overview · 2025
General Payments
$186.97
9 reported records · 4 companies
Healthcare provider profile · identity verified
Ernesto Malave, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · KILLEEN, TX · NPI 1609985852
Verified facts
What the public records show
CMS Open Payments records show Ernesto Malave, M.D. received $186.97 in general payments during 2025 across 9 reported records.
GlaxoSmithKline, LLC. accounted for 56.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 428 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Tresiba by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trulance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $105.30 | 56.3% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $33.17 | 17.7% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $28.31 | 15.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $20.19 | 10.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $186.97 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $105.30 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $33.17 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $28.31 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $20.19 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 65 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
65 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
428 | 77 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 594 | 172 |
| Lisinopril | Lisinopril | 477 | 146 |
| Ozempic | Semaglutide | 428 | 77 |
| Losartan Potassium | Losartan Potassium | 408 | 118 |
| Gabapentin | Gabapentin | 378 | 104 |
| Levothyroxine Sodium | Levothyroxine Sodium | 362 | 97 |
| Atorvastatin Calcium | Atorvastatin Calcium | 319 | 95 |
| Amlodipine Besylate | Amlodipine Besylate | 294 | 87 |
| Montelukast Sodium | Montelukast Sodium | 284 | 99 |
| Celecoxib | Celecoxib | 281 | 78 |
| Omeprazole | Omeprazole | 266 | 84 |
| Tramadol Hcl | Tramadol Hcl | 255 | 65 |
| Jardiance | Empagliflozin | 251 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 246 | 79 |
| Zolpidem Tartrate | Zolpidem Tartrate | 217 | 44 |
| Farxiga | Dapagliflozin Propanediol | 216 | 55 |
| Carvedilol | Carvedilol | 208 | 58 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 197 | 50 |
| Duloxetine Hcl | Duloxetine Hcl | 162 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 149 | 46 |
| Alprazolam | Alprazolam | 142 | 31 |
| Mounjaro | Tirzepatide | 141 | 30 |
| Ibuprofen | Ibuprofen | 136 | 56 |
| Symbicort | Budesonide/Formoterol Fumarate | 132 | 20 |
| Eszopiclone | Eszopiclone | 129 | 38 |
| Nebivolol Hcl | Nebivolol Hcl | 126 | 35 |
| Trulicity | Dulaglutide | 126 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 121 | 48 |
| Tresiba Flextouch U-200 | Insulin Degludec | 115 | 26 |
| Meloxicam | Meloxicam | 107 | 30 |
| Januvia | Sitagliptin Phosphate | 100 | 25 |
| Tresiba Flextouch U-100 | Insulin Degludec | 99 | 26 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 98 | 29 |
| Azithromycin | Azithromycin | 94 | 73 |
| Eliquis | Apixaban | 88 | 19 |
| Pantoprazole Sodium | Pantoprazole Sodium | 88 | 35 |
| Simvastatin | Simvastatin | 88 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 80 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 80 | 24 |
| Furosemide | Furosemide | 79 | 34 |
| Metformin Hcl | Metformin Hcl | 75 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 75 | 23 |
| Metformin Hcl Er | Metformin Hcl | 74 | 21 |
| Pregabalin | Pregabalin | 74 | 21 |
| Trazodone Hcl | Trazodone Hcl | 74 | 26 |
| Kerendia | Finerenone | 70 | 16 |
| Mometasone Furoate | Mometasone Furoate | 70 | 29 |
| Prednisone | Prednisone | 70 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 67 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 65 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 65 | 18 |
| Lidocaine | Lidocaine | 62 | 23 |
| Linzess | Linaclotide | 59 | 24 |
| Clonazepam | Clonazepam | 56 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 56 | 22 |
| Lorazepam | Lorazepam | 56 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 52 | 17 |
| Meclizine Hcl | Meclizine Hcl | 51 | 21 |
| Sertraline Hcl | Sertraline Hcl | 51 | 15 |
| Allopurinol | Allopurinol | 49 | 16 |
| Fluconazole | Fluconazole | 48 | 23 |
| Dicyclomine Hcl | Dicyclomine Hcl | 45 | 13 |
| Ammonium Lactate | Ammonium Lactate | 44 | 19 |
| Potassium Chloride | Potassium Chloride | 44 | suppressed |
| Mirtazapine | Mirtazapine | 42 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 41 | suppressed |
| Memantine Hcl | Memantine Hcl | 41 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 40 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 40 | 13 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 40 | suppressed |
| Acyclovir | Acyclovir | 39 | 15 |
| Enalapril Maleate | Enalapril Maleate | 39 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 39 | suppressed |
| Finasteride | Finasteride | 38 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | suppressed |
| Ezetimibe | Ezetimibe | 35 | suppressed |
| Famotidine | Famotidine | 35 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 22 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 33 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 31 | 17 |
| Bupropion Xl | Bupropion Hcl | 30 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 30 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 30 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 30 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 27 |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 12 |
| Alendronate Sodium | Alendronate Sodium | 27 | suppressed |
| Pentoxifylline | Pentoxifylline | 27 | suppressed |
| Amoxicillin | Amoxicillin | 25 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 24 | suppressed |
| Gemfibrozil | Gemfibrozil | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Latanoprost | Latanoprost | 24 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 23 | 11 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 23 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 23 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Temazepam | Temazepam | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Naproxen | Naproxen | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 21 | suppressed |
| Trulance | Plecanatide | 21 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 20 | 17 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Ibu | Ibuprofen | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 11 |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Easy Touch | Syring-Needl,disp,insul,0.3 Ml | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 11 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 11 | suppressed |
| Tresiba | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $186.97 · 9 records | GlaxoSmithKline, LLC. | FREESTYLE LIBRE 3, TRELEGY ELLIPTA, Wegovy, XIFAXAN | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error